Skip to content

A Clinical Trial on No-touch Vein Graft (NT-graft) in Coronary Surgery

A Nordic, Multicentre, Prospective, Randomized, Register Based, Clinical Trial on No-touch Vein Graft (NT-graft) in Coronary Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03501303
Acronym
SWEDEGRAFT
Enrollment
902
Registered
2018-04-18
Start date
2018-04-20
Completion date
2023-11-17
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Heart Disease

Brief summary

The primary objective in this study is to investigate if vein grafts harvested and implanted with the non-touch technique are superior to conventional vein graft technique with respect to mid-term patency, in patients undergoing CABG surgery.

Detailed description

Coronary artery bypass grafting (CABG) is the most common surgical procedure aimed against ischemic heart disease (IHD) in Sweden. Early and late success of CABG is the result of sustained patency of the bypass grafts. The choice of conduit (graft) for CABG has been shown to impact graft patency. The excellent early and late patency of in situ left internal thoracic artery (LITA) has stimulated the use of other arterial grafts, such as the radial artery (RA) and the right internal thoracic artery (RITA). However, target coronary vessels/lesions are limitations for the use of RITA and RA, and concerns regarding postoperative sternal wound infection with increases of early morbidity and mortality are reasons for limited use of bilateral ITA. The saphenous vein grafts (SVG), together with the left internal thoracic artery, are still the most commonly used conduits in CABG surgery. Vein graft failure is associated with recurrence of angina and one of the primary reasons for reintervention, either by redo CABG or percutaneous coronary intervention (PCI). Early vein graft failure is not uncommon, and it was shown in the PREVENT IV multi-center trial6, that vein graft failure (occluded or stenosed) had occurred in 27% of all vein grafts at one year. Despite this, SVG remains as an important conduit for most patients in contemporary bypass surgery and every effort should focus on promoting short and long-term patency of SVG. Previous studies by Souza have demonstrated that harvesting the SVG with a pedicle of surrounding tissue and without vein graft distension, the so-called No touch technique (NT), significantly improve patency compared with conventional technique i.e. stripping the vein of all adventitial tissue and distension prior to implantation. An international multi center randomized controlled clinical trial, (SUPERIOR SVG, NCT01047449) including 12 centers and 250 patients, was recently presented and showed favorable but not significant results for No touch vein grafts compared to conventional vein grafts. The protocol did not include cardiac computed tomography angiography (CCTA) for every patient which is an important difference compared to our planned study. The major limitation regarding the putative benefit of NT technique of vein harvesting is that most of the data has all been derived from a single center. The surgical vein graft harvesting technique for NT grafts is more demanding. Therefore, there is a clear clinical equipoise to perform a multi-center randomized clinical trial to validate the excellent single-center results and determine whether the NT technique is reproducible, feasible and generalizable.

Interventions

Veins for CABG is harvested with the no touch technique

Veins for CABG is harvested with the Control technique.

Sponsors

Uppsala University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

In an online randomization module the randomization will be performed with permuted block randomization to 1:1 ratio.

Eligibility

Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No

Inclusion criteria

* first time CABG patients * age up to 80 years at the time for inclusion * need for at least one vein graft * able to provide informed consent and accepted for isolated primary non-emergent CABG.

Exclusion criteria

* unable to use greater saphenous vein grafts (SVG) due to previous vein stripping or poor vein quality * allergy to contrast dye * renal failure with glomerular filtration rate (GFR)\<15 ml/min * coagulation disorders * excessive risk of wound infection * participation in other interventional trial on grafts * any condition that seriously increases the risk of non-compliance or loss of follow-up

Design outcomes

Primary

MeasureTime frameDescription
Saphenous vein grafts (SVGs) occluded/stenosedFollow up period is from inclusion and surgery up to at least two years after.The proportion of patients with graft failure defined as: SVGs occluded/stenosed \>50% on CCTA or has undergone percutaneous intervention to a vein graft or died within two years after CABG.

Secondary

MeasureTime frameDescription
Major adverse cardiac events (MACE) 1Follow up period is from inclusion and surgery up to at least two years after.The frequency of incidence of all cause death
MACE 2Follow up period is from inclusion and surgery up to at least two years after.The frequency of myocardial infarction
MACE 3Follow up period is from inclusion and surgery up to at least two years after.The frequency of repeated revascularization
Vein-graft stenosisFollow up period is from inclusion and surgery up to at least two years after.The frequency of non-significant vein graft stenosis (20-50%)
Perivascular inflammationFollow-up period is from inclusion and surgery up to at least 2 years after.Perivascular fat attenuation index (FAIPVAT) around right coronary artery, no-touch saphenous vein grafts, and left internal mammary artery grafts
Wound complicationsFollow up period is from inclusion and surgery up to at least two years after.The frequency of incidence of postoperative leg wound complications from the harvesting site.

Other

MeasureTime frameDescription
Questions about wound healingAt 3 months and 2 years after CABG surgery.The questionnaires will be assessed by Telephone.
Questions about Quality of LifeAt 2 years after CABG surgery.The patients will be interviewed about problems with angina (SAQ-7, Seattle Angina Questionnaire-7). The questionnaire will be assessed by telephone.

Countries

Denmark, Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026